Eli Lilly: clinical trial for Covid-19 patients
(CercleFinance.com) - Eli Lilly announces the start of a phase 3 clinical trial with baricitinib for patients hospitalised due to Covid-19.
The first patient was enrolled in a randomised double-blind, placebo-controlled phase 3 study to assess the effectiveness and safety of baricitinib, an oral inhibitor in adults hospitalised with Covid-19.
Baricitinib is approved in 70 countries as treatment for adults with moderately to severely active rheumatoid arthritis.
The group plans to register 400 patients in the trial, with data expected in the coming months. The study will be conducted in the United States, Europe and Latin America.
Copyright (c) 2020 CercleFinance.com. All rights reserved.